EQUILLIUM, INC. Notes Payable, Noncurrent
EQUILLIUM, INC. (EQ) had Notes Payable, Noncurrent of $1.84 million as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities › Notes Payable, Noncurrent
us-gaap:LongTermNotesPayable · last filed 2024-03-25
- 2023-03-31: Notes Payable, Noncurrent $1.84M.
- 2022-12-31: Notes Payable, Noncurrent $3.24M.
- 2022-09-30: Notes Payable, Noncurrent $4.62M.
- 2022-06-30: Notes Payable, Noncurrent $5.99M.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2023-03-31 | $1.84M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.24M 10-K · filed 2024-03-25 |
| 2022-09-30 | $4.62M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $5.99M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $7.37M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $8.75M 10-K · filed 2023-03-23 |
| 2021-09-30 | $8.87M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $10.07M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $7.51M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $8.28M 10-K · filed 2022-03-23 |
| 2020-09-30 | $9.04M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $9.81M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $9.75M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $9.68M 10-K · filed 2021-03-24 |
| 2019-09-30 | $9.62M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |